I notice the filing content is cut off mid-sentence. However, there is sufficient substantive content to produce an article based on the financial data available through Q3 2026.

MaxCyte, Inc. filed its quarterly report on Form 10-Q with the SEC on November 10, 2026, covering the fiscal quarter and nine-month period ended September 30, 2026, disclosing revenue growth alongside a reduced net loss compared to the prior-year period.

Key Highlights

  • Quarterly revenue of $10.152 million for the three months ended September 30, 2026, up from $6.829 million in the same period of 2025, according to the filing.
  • Nine-month revenue of $27.074 million for the period ended September 30, 2026, compared to $25.726 million for the same period in 2025, the company disclosed.
  • Net loss narrowed to $4.762 million for Q3 2026, compared to a net loss of $12.416 million in Q3 2025, the filing reported.
  • Nine-month net loss of $18.386 million for 2026, compared to $35.034 million for the same period in 2025, according to the registrant.
  • Total assets of $182.483 million as of September 30, 2026, down from $202.507 million at December 31, 2025, the filing stated.
  • Treasury stock of $5.500 million (4,260,534 shares) appeared on the September 30, 2026 balance sheet, with no treasury stock recorded at December 31, 2025, the filing disclosed.
  • 103,250,292 shares of common stock were issued and outstanding as of November 6, 2026, per the filing's cover page.

MaxCyte Q3 2026 Financial Results: Revenue Gains and Reduced Operating Losses

According to the Form 10-Q filed November 10, 2026 on NASDAQ:MXCT, MaxCyte reported third-quarter 2026 revenue of $10.152 million, an increase from $6.829 million in Q3 2025. For the nine months ended September 30, 2026, revenue totaled $27.074 million versus $25.726 million in the comparable prior-year period. The company reported gross profit of $8.468 million for the quarter and $22.146 million for the nine-month period, compared to $5.233 million and $21.114 million, respectively, in 2025.

Total operating expenses for the nine months ended September 30, 2026 were $44.604 million, the filing stated, a substantial reduction from $61.785 million in the same period of 2025. The prior-year period included $3.058 million of restructuring expense that did not recur in 2026. Research and development costs declined to $10.984 million for the nine months ended September 30, 2026, from $17.488 million in the same period of 2025. Sales and marketing expenses were $11.006 million for the nine-month period, down from $15.420 million. General and administrative expenses were $19.777 million for the nine months ended September 30, 2026, compared to $22.634 million in 2025, the company disclosed.

The registrant reported a basic and diluted net loss per share of $0.05 for Q3 2026, compared to $0.12 in Q3 2025, based on weighted-average shares outstanding of 103,537,926 and 106,613,075, respectively. As of September 30, 2026, the company held cash and cash equivalents of $13.372 million and short-term investments of $87.908 million. The accumulated deficit stood at $279.869 million as of September 30, 2026, up from $261.483 million at December 31, 2025. The company also disclosed an accounts receivable balance of $12.054 million at September 30, 2026, compared to $3.503 million at December 31, 2025. The filing identified the company as a smaller reporting company and an emerging growth company.

What Was Disclosed

MaxCyte filed its Form 10-Q for the quarter ended September 30, 2026, reporting higher quarterly and nine-month revenue compared to 2025, reduced operating expenses, a narrowed net loss, and the appearance of treasury stock on its balance sheet for the first time in the periods presented.